BeOne Medicines Ltd. — Director's Dealing 2025

May 15, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BeiGene, Ltd. (BGNE)
CIK: 0001651308
Period of Report: 2025-05-13

Reporting Person: Wang Xiaodong (Director, Chair, Scientific Advisory Brd)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-05-13	American Depositary Shares	M	41760	$6.50	Acquired	41760	Direct
2025-05-13	American Depositary Shares	S	10221	$222.8257	Disposed	31539	Direct
2025-05-13	American Depositary Shares	S	21235	$223.4091	Disposed	10304	Direct
2025-05-13	American Depositary Shares	S	10104	$224.3213	Disposed	200	Direct
2025-05-13	American Depositary Shares	S	200	$225.68	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-05-13	Share Option (Right to Buy)	$0.50	M	542880	Disposed	2025-07-19	Ordinary Shares (542880)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares	5082165	Direct
Ordinary Shares	1025063	Indirect
Ordinary Shares	3953100	Indirect
Ordinary Shares	50	Indirect

Footnotes

F1: These securities are held by a family trust, the beneficiaries of which are the Reporting Person's family members, for which the Reporting Person disclaims beneficial ownership.

F2: These securities are held by Wang Investment LLC, of which 99% of the limited liability company interest is owned by two grantor retained annuity trusts, of which the Reporting Person's wife is a trustee, for which the Reporting Person disclaims beneficial ownership.

F3: These securities are held by the spouse of the Reporting Person.

F4: Each American Depositary Share represents 13 Ordinary Shares.

F5: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on August 12, 2024.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $222.03 to $223.02, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $223.03 to $224.02, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $224.03 to $224.77, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

F9: These securities vest over a five-year period as follows: 20% on July 19, 2016, and the remaining in 48 successive equal monthly installments, subject to continued service. The expiration date of the share option is July 19, 2025.